In the first case, prostate-specific membrane antigen (PSMA) labeled with both [18F] or [68Ga] is a radiopharmaceutical that has proved its high diagnostic accuracy for the evaluation of PCa and enables the selection of patients that could be treated with [177Lu]Lu-PSMA-617. Here, FOLH1 is linked to posterior cortical atrophy.